<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>CD5 is a T-cell marker aberrantly expressed in B-cell <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> and mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Other B-cell <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, including Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, are usually CD5- </plain></SENT>
<SENT sid="2" pm="."><plain>We report 4 cases of de novo CD5+ Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0001909'>leukemia</z:hpo> in elderly patients, <z:hpo ids='HP_0000001'>all</z:hpo> of whom were in a leukemic phase and had variable lymph node and splenic involvement </plain></SENT>
<SENT sid="3" pm="."><plain>The blasts were typically medium sized, with folded nuclei, distinct but not prominent nucleoli, and moderate amounts of somewhat vacuolated basophilic cytoplasm; they were terminal deoxynucleotidyl transferase--negative and surface immunoglobulin--positive </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 4 cases demonstrated c-myc rearrangement, but none had t(14;18), t(11;14), or cyclin D1 overexpression or rearrangement </plain></SENT>
<SENT sid="5" pm="."><plain>Only 1 patient achieved complete remission after hyper-CVAD (hyperfractionated <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="41879">dexamethasone</z:chebi>) therapy </plain></SENT>
<SENT sid="6" pm="."><plain>One patient responded poorly to hyper-CVAD, and 2 patients died during induction chemotherapy </plain></SENT>
<SENT sid="7" pm="."><plain>These rare cases of aggressive lymphoid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> with CD5 positivity and molecular features associated with Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0001909'>leukemia</z:hpo> are best classified as Burkitt <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>However, the morphologic and immunophenotypic similarity to the blastoid variant of mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> are diagnostically challenging </plain></SENT>
<SENT sid="9" pm="."><plain>The diseases can be distinguished at the genetic level, since Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> involves the rearrangement of c-myc, and mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> usually the overexpression or rearrangement of cyclin D1 </plain></SENT>
</text></document>